Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026
Iovance will present five abstracts at ESMO 2026 (Oct 23-27, Madrid), including two orals: final Phase 2 data for lifileucel plus pembrolizumab in ICI-naive advanced melanoma, and first-ever TIL data in UPS and DDLPS soft tissue sarcomas from an MSKCC-led pilot trial. An indirect-comparison poster suggests lifileucel may roughly double four-year overall survival versus standard of care in anti-PD-1-resistant advanced melanoma.
Key figures
- Drug Name
- lifileucel (Amtagvi)
- Phase Of Trial
- Phase 3 (TILVANCE-301); registrational Phase 2 (SARATOGA)
- Abstracts
- 5
- Atc count
- nearly 100 authorized treatment centers
- Oral presentations
- 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.